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Abstract
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is potentially curative in a variety of hematological
malignancies. Graft-vs.-host disease (GvHD) remains a life-threatening complication. Standard treatment is high-dose
(HD) corticosteroids. Steroid-refractory (SR) GvHD is associated with poor prognosis. At present, second-line treatment is
ill-defined and includes a number of agents. Novel insights into the pathophysiology of acute GvHD (aGvHD) highlight
the relevant role of the host inflammatory response governed by several kinase families, including Janus kinases (JAK)
1/2. Ruxolitinib, a JAK1/2 inhibitor approved for intermediate-2/high-risk myelofibrosis, was recently employed in
SR-GvHD with encouraging overall response rates. Clinical experience however remains limited.
Case presentation: A 51-year-old male with refractory anemia with excess blast type-2 underwent a myeloablative
allogeneic HSCT from a 9/10 HLA-matched unrelated donor after conditioning with busulfan and cyclophosphamide.
GvHD prophylaxis consisted of cyclosporine, methotrexate, and thymoglobulin. CD34+ cells/kg infused were 8.69 ×
106 kg. On day 29, the patient developed overall grade IV aGvHD with biopsy proven stage IV gastrointestinal (GI)
GvHD refractory to HD corticosteroids. Patient conditions rapidly deteriorated and became critical despite the addition
of mycophenolate mofetil and budesonide. On day 33, Ruxolitinib was started, and on day 39 the patient clinical
conditions gradually improved. Complete resolution of aGvHD was also confirmed by histology on day 54.
Conclusions: At 5 months from HSCT, the patient is well and in continuous hematological complete remission
without flare of GvHD. Ruxolitinib was discontinued on day 156. Ruxolitinib is feasible and effective in SR-aGvHD
though large prospective clinical trials are warranted.
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Background
Allogeneic hematopoietic stem cell transplantation (HSCT)
is potentially curative for several hematopoietic malig-
nancies. Acute graft-vs.-host disease (aGvHD) remains
the major cause of morbidity and mortality. High-dose
corticosteroids (methylprednisolone, 1–2 mg/kg per day)
are currently considered standard first-line treatment.
However, a remarkable number of patients do not respond
[1]. Estimated incidence of steroid-refractory aGvHD
(SR-GvHD) is some 40 %, and it is associated with poor
long-term survival of 5–30 % [2–4]. At present, there are
no well-defined treatment approaches although several
second-line therapies aimed at inactivating alloreactive
donor T cells, pro-inflammatory cytokines or their
receptors have been investigated. The weighted average
6-month survival from 25 retrospective studies or
phase II trials was 49 % [2]. Among others, agents used
included anti-thymocyte globulin, mycophenolate mo-
fetil, anti-CD25 monoclonal antibody (basiliximab),
anti-tumor necrosis factor alpha (infliximab and etaner-
cept), anti-interleukin 2 receptor-alpha (inolimomab),
anti-CD52 (alemtuzumab), pentostatin, m-Tor inhibitors
and extracorporeal photoapheresis [5–13]. Since clinical
trials in SR-GvHD are difficult to design given the hetero-
geneity of treatment policies, direct comparisons of differ-
ent agents have not been possible.
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Case presentation
A 51-year-old male without significant comorbidities and
irrelevant past medical history was diagnosed with refrac-
tory anemia with excess blast type-1 (RAEB-1) in 2013
and evolved to RAEB-2 after 24 months. Overall, the pa-
tient had a high risk score both by the International (IPSS)
and by the WHO prognostic scoring systems (WPSS).
Blast count was 15 % on bone marrow biopsy and 11 %
on marrow aspirate. Other features included trisomy 8 by
cytogenetic analysis and two cytopenias—neutropenia and
thrombocytopenia—in the peripheral blood. He never
required red blood cell or platelet transfusions. He was
initially treated with 2 cycles of induction chemotherapy
with fludarabine (30 mg/m2, days 1–5), high-dose cytara-
bine (2000 mg/m2, days 1–5), and idarubicin (10 mg/m2,
days 1–3). Complete remission by histology and by flow
cytometry was obtained. However, FISH analysis showed
persistent trisomy 8. The patient underwent an allogeneic
HSCT with mobilized peripheral blood stem cells from
a 9/10 HLA-matched (antigenic mismatch at HLA-A)
unrelated donor. Conditioning regimen was busulfan
(3.2 mg/kg/day; days −7 to −4) and cyclophosphamide
(60 mg/kg/day; days −3 and −2). GvHD prophylaxis
consisted of cyclosporine (CsA) (1.5 mg/kg twice daily,
from day −1), methotrexate (15 mg/m2, 24 h after trans-
plant, then 10 mg/m2 on days 3, 6, and 11), and thymoglo-
bulin (2.5 mg/kg on days −3 and −2). CD34+ cells/kg
infused were 8.69 × 106. Gut decontamination with antibi-
otics after HSCT was not scheduled. On day 13, the pa-
tient stopped oral intake because of grade III mucositis.
On day 22, he developed a maculo-papular rash on 50 %
of his body surface area (stage 2) and mild (500 ml/24 h)
watery diarrhea (stage 1), without fever and/or liver
function tests abnormalities suggestive of aGVHD. Stool
cultures ruled out gastrointestinal (GI) bacterial, viral or
parasitic infections. A chest X-ray ruled out pulmonary
infiltrates. Diagnosis of overall grade II aGVHD was made
and intravenous (i.v.) corticosteroids at 2 mg/kg/day were
promptly started on the same day. However, diarrhea
worsened rapidly over the following days to stage 4 GI
aGvHD with over 2500 mL/24 h of diarrhea and increas-
ing painful abdominal cramps (Table 1). Clinical condi-
tions did not improve despite the combination of
cyclosporine, high-dose steroids and the addition of oral
budesonide (3 mg three times per day) on day 28 and i.v.
mycophenolate mofetil (MMF) (1 g three times per
day) on day 29. An endoscopic evaluation of the upper
GI tract with multiple biopsies on day 33 confirmed the
diagnosis of aGvHD (Fig. 1a–c). Patient's clinical condi-
tions rapidly deteriorated. Oral Ruxolitinib was started
at 5 mg twice per day on day 33. Stools volume pro-
gressively and steadily decreased to less than 1000 mL
on day 39. MMF was stopped on the same day given its
unlikely clinical efficacy and to reduce immunosuppression.
Clinical conditions gradually improved. Neutrophil and
platelet engraftment (defined as the first of 3 consecutive
days of neutrophils ≥500/uL and as the first of 7 consecu-
tive days with platelet counts ≥20,000/uL without transfu-
sion support, respectively) occurred at days 17 and 19.
Platelet counts were ≥300.000/uL on day 28 and then
dropped below 100,000/uL on day 49 and remained stable
around 40,000–50,000/uL until discharge (with concurrent
oral Ruxolitinib at 5 mg twice daily). Hemoglobin values
peaked at 136 g/L on day 31 and dropped below 100 g/L
on day 35. Overall, 4 units of red blood cells were required
during hospitalization. Skin lesions disappeared completely
by day 50. On day 45, the patient resumed oral food intake
without nausea and/or vomiting and by day 61 stools were
formed. A second endoscopy with multiple biopsies on day
54 revealed no residual signs of aGvHD in the GI tract
(Fig. 1d). Bone marrow biopsy on day 64 showed a hypo-
cellular marrow with normal myeloid maturation without
evidence of disease recurrence and full donor engraft-
ment by mixed-chimerism analysis. On day 70, the patient
was discharged. Ruxolitinib was initially reduced be-
cause of progressive pancytopenia to 5 mg per day on
day 100 and to 5 mg every other day on day 107. It was
Table 1 Patient timeline clinical history




22 aGvHD onset: diarrhea (st.I) and skin (st.II). Started
PDN-equivalent 2 mg/kg/iv
28 Diarrhea exceeded 1500 mL/day (st.III) and started
budesonide 3 mg tid po
29 Diarrhea exceeded 2000 mL/day (st.IV) and started
MMF 1 g tid iv
33 EGDS with biopsies (GvHD confirmation). Started
Ruxolitinib 5 mg bid
36 Steroid taper
39 Diarrhea below 1000 mL and Ruxolitinib 5 +
10 mg/day. Stop MMF
45 Resumed oral food intake
49 Switch to oral CsA
54 EGDS with biopsies: no signs of GvHD
61 Switch PDN po
66 Reduced Ruxolitinib to 5 mg bid
70 Patient discharged
100 Reduced Ruxolitinib to 5 mg/day
135 Steroid stopped
156 Ruxolitinib stopped
abbreviations: HSCT hematopoietic stem cell transplantation, aGvHD acute
graft-vs.-host disease, PDN prednisone, iv intravenously, po orally, MMF
mycophenolic acid, EGDS esophagous-gastro-duodenoscopy, CsA cyclosporine
A, bid twice daily, tid three times a day, st stage
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resumed at 5 mg per day on day 113 because of soften
stools and abdominal discomfort with prompt improve-
ment of GI symptoms. Platelet counts progressively
raised to ≥80,000/uL.
Cytokine measurement
Serum levels of tumor necrosis factor alpha (TNF-α) and
interleukin-6 (IL-6) were measured in serum samples from
day +27 (before the start of Ruxolitinib) and day +56 (after
23 days of treatment), by Becton Dickinson Biosciences
Human Inflammatory Cytokine kit. Interestingly, we ob-
served a decrease of both these pro-inflammatory markers
during Ruxolitinib treatment (Fig. 2). We cannot, however,
rule out a potential effect of glucocorticoids and mycophe-
nolic acid [14, 15].
Conclusions
Donor T cell immune response to recipient antigens
represents a key mechanism of GvHD and is combined
with a massive production of inflammatory cytokines
such as TNF-α, IL-1, IL-6 and IL-2-R. Cytokine-induced
activation of the various effector cells—including T cells,
dendritic cells, and neutrophils—is mediated by the inter-
play between cytokine receptors and a number of special-
ized kinases [16]. Family members of Janus kinases (JAK)
are among the most studied. Ruxolitinib is a selective oral
JAK1/2 inhibitor approved for the treatment of patients
with intermediate-2 or high-risk primary myelofibrosis
[17, 18]. Spleen size reduction and improvement of consti-
tutional symptoms are directly correlated with inhibition
of JAK-STAT signal transducer hyperactivity and with re-
duction of both effector cells activity and flogistic cytokine
signature [19]. Apart from its ability to depress the
pro-inflammatory environment of GvHD, Ruxolitinib
shapes T cell mediated immune response toward a FoxP3+
regulatory T cell (Treg) polarization mostly by a sparing
mechanism of the JAK3-STAT5 pathway [18]. Tregs im-
prove signs and symptoms of aGvHD and promote immu-
notolerance [19–23]. These mechanisms have been shown
on murine models [14] and also form the rationale for the
potential efficacy of Ruxolitinib in the treatment of GvHD
in man.
Only a few clinical experiences have been reported so
far. Spoerl et al. [24] explored JAK1/2 inhibition during
aGvHD both in a major HLA-mismatched murine model




Fig. 1 Histology studies (H&E). a–c Gastrointestinal acute grade I GVHD:
focal apoptosis of crypt epithelial cells (white arrows) without abscess or
crypt destruction. A clear lymphocytic infiltration of the lamina propria is
not present. Moderate mucosal atrophy can be observed. d Duodenum
at day +54 post-transplant: complete reconstitution of the mucosa with
disappearance of apoptotic crypt cells (courtesy of D. Novero, Pathology,
University of Turin)
Fig. 2 Serum levels of TNF-α and IL-6. TNF-α decreased from
10 pg/mL at day 27 (while on high-dose steroids) to 5 pg/mL at
day 54, while IL-6 decreased from 2.3 to 1.5 pg/mL (values are
expressed as percentage)
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SR-aGvHD (GI in 2 and skin in 4). In the murine
model, Ruxolitinib was associated with a significantly
prolonged survival with reduced weight loss and GvHD
severity by histology studies and suppression of the
serum inflammatory cytokine profile. Moreover, a reduc-
tion of donor alloreactive T cells with a concomitant ex-
pansion of CD4+ FoxP3+ Treg in GvHD target organs
demonstrated the ability of Ruxolitinib to shift T cell
phenotype. In HSCT recipients, response rates were opti-
mal with clinical regression in all and a marked reduction
of pro-inflammatory cytokines such as IL-6 and soluble
IL-2 receptor. Ruxolitinib was employed at a starting dose
of 5 mg twice per day daily with a dose increase to 10 mg
twice per day. Neither thrombocytopenia nor anemia were
reported. A recent retrospective multi-center survey on 95
HSCT recipients with SR-GVHD—54 acute and 51
chronic GvHD (cGvHD), reported the most significant
clinical experience so far completed [25]. Median prior
lines of treatment were three (range: 1–7 for aGvHD;
1–10 for cGvHD). Overall response rate was 81.5 % in
the aGvHD group (44/54) with 57 % (25/44) complete
remissions and of 85.4 % (35/41) in the cGvHD group,
respectively. Overall survival was 79 and 97.4 %. Among
responders, GvHD flare was 6.8 % for aGvHD and 5.7 %
for cGvHD patients. Side effects such as cytopenia (55.6
and 17.1 % in the aGvHD and cGvHD group, respectively)
and cytomegalovirus (CMV) reactivation (33.3 and
14.6 %) were comparable to those reported with other
agents including steroids, infliximab, alemtuzumab, my-
cophenolate mofetil, or cyclosporine. Overall, one of
the concerns was the loss of a graft-vs.-leukemia effect,
given the pharmacological interference with the JAK1/2
signal pathway; however, the reported rate of disease
recurrence after Ruxolitinib was of 9.3 and 2.4 % of the
patients in the aGVHD and cGVHD groups, respectively.
Initial signs of improvement (partial response) of GVHD
symptoms were observed 6 days from the start of Ruxoliti-
nib and complete resolution after 3 weeks of treatment.
These findings are similar to those reported by Zeiser et
al. (median time to response 1.5 weeks, range 1–11). A
possible synergistic role with budesonide and MMF can-
not be completely ruled out even though these agents
were administered only for a very few days. The most ef-
fective Ruxolitinib tapering schedule remains to be de-
fined, given the limited clinical experience. Our schedule
was purely based on clinical grounds in the light of GvHD
signs/symptoms, worsening of cytopenias, or viral reacti-
vation. A steroid-sparing effect in chronic GvHD has also
recently been proposed [26] with encouraging results. A
similar role in aGvHD has not yet been reported. Ruxoliti-
nib dose-dependent cytopenias are usually expected dur-
ing treatment [27] even though, in our patient, other
factors such as GvHD itself and prolonged immunosup-
pressive therapy with several agents may have been
involved [28]. At 5 months from HSCT, the patient is
doing well, with full donor mixed chimerism and in con-
tinuous complete remission (confirmed at bone marrow
biopsy on day 148) with no signs and/or symptoms of
GvHD on CsA taper. Prednisone was stopped on day
135 and Ruxolitinib on day 156. Of note, there was no
CMV (though both donor and recipient were CMV
seronegative)- nor Epstein Barr Virus-DNAemia break-
through. Overall, our clinical findings suggest that Rux-
olitinib played a fundamental role in the successful GvHD
treatment of our patient. SR-GvHD is a challenging
complication with no current standard treatment. GI
tract involvement is life-threatening also in the light of
the long process required for a complete repair of the
intestinal mucosa. Therapeutic efficacy of Ruxolitinib is
underlined by recent biological insights into the rele-
vant role played by the JAK-STAT signaling pathway in
aGvHD. However, treatment duration and possible im-
pacts on graft-vs.-leukemia and immune-responses
against infections remain a matter of debate. Thus, lar-
ger clinical phase II–III controlled trials and compari-
sons with best available treatments are warranted. A
German multi-center phase II clinical trial on Ruxoliti-
nib in SR-aGvHD is due to start accrual this fall
(NCT02396628).
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